DxMan: All well and good, but Mr. Franklin never promised anybody he'd get that a/c unit to them by next summer, July at the latest. You see my point? To the casual observer and, to a lesser but growing extent the LT investor, it appears these guys are clueless at best, scoundrels at worst. Do I think either of those? No. It's not me I'm worried about. It's the market, and the impressions left upon the market that grow exponentially with each passing quarter and with each failed promise. The unstated requirements put upon the release of a product that you've mentioned are indeed real, but also communicable, even to the layman and casual biotech investor. Left unsaid, they breed suspicion and mold. Both of which are nearly impossible to get rid of. I see tough times ahead for this stock because of the poor and lax choices made by this company. Here's an example: you've read my posts for months. You've acquired a sense of who I am and what I believe, politically, socially, economically, and that sense most likely grew in stages: doubt, agenda, disagreement, agreement. That's what IR should be doing right now and should have been doing all along. Talking. Pitching woo. Create and then market. Offer the product (stock). Some will love it, some will lump it. The pipeleine and the stock are two different entites with two different marketing demands, but they cannot be torn asunder. In order for the company to be successful, the stock cannot be seperated from the market any more than the SoftPap can be seperated from it's market. Both scenarios would guarantee doom.
AI
Market Data 
Markets 
